Setmelanotide (also named RM-493, BIM-22493, IRC-022493, and brand name Imcivree) is a synthetic cyclic MC4R agonist approved by the Food and Drug Administration and European Medicines Agency and shown to be effective in reducing body weight in patients with obesity caused by bi-allelic pathogenic POMC, PCSK1, or LEPR variants (35, 36), as well as in diet-induced animal models (35). This evidence concerns the gene MC4R and obesity disorder.